JPWO2022232179A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022232179A5 JPWO2022232179A5 JP2023566493A JP2023566493A JPWO2022232179A5 JP WO2022232179 A5 JPWO2022232179 A5 JP WO2022232179A5 JP 2023566493 A JP2023566493 A JP 2023566493A JP 2023566493 A JP2023566493 A JP 2023566493A JP WO2022232179 A5 JPWO2022232179 A5 JP WO2022232179A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- minutes
- dmt
- administration
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 35
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 claims 17
- 230000036765 blood level Effects 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 239000007919 dispersible tablet Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 235000011475 lollipops Nutrition 0.000 claims 1
- 229940041672 oral gel Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179679P | 2021-04-26 | 2021-04-26 | |
| US63/179,679 | 2021-04-26 | ||
| PCT/US2022/026396 WO2022232179A1 (en) | 2021-04-26 | 2022-04-26 | Novel n,n-dimethyltryptamine compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517738A JP2024517738A (ja) | 2024-04-23 |
| JP2024517738A5 JP2024517738A5 (https=) | 2025-05-07 |
| JPWO2022232179A5 true JPWO2022232179A5 (https=) | 2025-05-07 |
Family
ID=83694712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566493A Pending JP2024517738A (ja) | 2021-04-26 | 2022-04-26 | 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11602521B2 (https=) |
| EP (1) | EP4329879A4 (https=) |
| JP (1) | JP2024517738A (https=) |
| KR (1) | KR20240000516A (https=) |
| CN (1) | CN117320711A (https=) |
| AU (1) | AU2022267240A1 (https=) |
| BR (1) | BR112023022195A2 (https=) |
| CA (1) | CA3216889A1 (https=) |
| CL (1) | CL2023003191A1 (https=) |
| IL (1) | IL308074A (https=) |
| MX (1) | MX2023012651A (https=) |
| WO (1) | WO2022232179A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| IL308816A (en) * | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| KR20250005175A (ko) * | 2022-03-27 | 2025-01-09 | 지에이치 리서치 아일랜드 리미티드 | 양극성 장애의 치료를 위한 5-meo-dtm |
| CA3267555A1 (en) * | 2022-10-26 | 2024-05-02 | Atai Therapeutics, Inc. | Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use |
| DK202330319A1 (en) * | 2023-11-07 | 2025-05-27 | Fertin Pharma As | An adhesive oral disc for sustained release of cannabinoids |
| AU2024242138A1 (en) | 2023-03-31 | 2025-11-13 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| WO2025054397A1 (en) * | 2023-09-08 | 2025-03-13 | Atai Therapeutics, Inc. | Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof |
| WO2025076151A1 (en) * | 2023-10-02 | 2025-04-10 | Atai Therapeutics, Inc. | N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220079881A1 (en) | 2016-03-03 | 2022-03-17 | Ctt Pharma Inc. | Orally Administrable Composition |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| MD3927338T2 (ro) * | 2019-02-22 | 2025-03-31 | Gh Res Ireland Limited | Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale |
| EP4353314A3 (en) | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| JP7617927B2 (ja) * | 2019-12-31 | 2025-01-20 | キュア ファーマシューティカル， インコーポレイテッド | 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法 |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| WO2021259962A1 (en) * | 2020-06-22 | 2021-12-30 | University Of Zürich | Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy |
| CN116056705A (zh) * | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| CA3192617A1 (en) | 2020-09-20 | 2022-03-24 | Matthew BAGGOTT | Advantageous tryptamine compositions for mental disorders or enhancement |
-
2022
- 2022-04-26 MX MX2023012651A patent/MX2023012651A/es unknown
- 2022-04-26 KR KR1020237038175A patent/KR20240000516A/ko active Pending
- 2022-04-26 EP EP22796577.9A patent/EP4329879A4/en active Pending
- 2022-04-26 JP JP2023566493A patent/JP2024517738A/ja active Pending
- 2022-04-26 US US17/730,013 patent/US11602521B2/en active Active
- 2022-04-26 WO PCT/US2022/026396 patent/WO2022232179A1/en not_active Ceased
- 2022-04-26 IL IL308074A patent/IL308074A/en unknown
- 2022-04-26 CA CA3216889A patent/CA3216889A1/en active Pending
- 2022-04-26 AU AU2022267240A patent/AU2022267240A1/en active Pending
- 2022-04-26 CN CN202280031363.4A patent/CN117320711A/zh active Pending
- 2022-04-26 BR BR112023022195A patent/BR112023022195A2/pt unknown
-
2023
- 2023-10-25 CL CL2023003191A patent/CL2023003191A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025142338A5 (https=) | ||
| TW200815048A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| JP2010504312A (ja) | 活性成分の経粘膜投与のためのガレノス的方式 | |
| JP2001508038A (ja) | 粘膜表面および身体組織に付与可能な薬学的ゲル調製物 | |
| BRPI0711168A2 (pt) | composição transmucosal | |
| JP4597273B2 (ja) | 経口組成物 | |
| CN101505724A (zh) | 阿利吉仑的盖伦制剂 | |
| EP3641759B1 (en) | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva | |
| BRPI0711997A2 (pt) | preparaÇço farmacÊutica, uso de uma forma de dosagem, uso de uma combinaÇço de agentes ativos, mÉtodo para o tratamento terapÊutico de um indivÍduo e mÉtodo para a produÇço de uma forma de dosagem no formato de uma folha | |
| JPWO2022232179A5 (https=) | ||
| JP2023506545A (ja) | アゴメラチンを含有する経粘膜治療システム | |
| Sheoran | Buccal drug delivery system: A review | |
| CN107949378A (zh) | 用于施予局部麻醉的速效口溶膜剂 | |
| JP2023506537A (ja) | アゴメラチンを含有する経粘膜治療システム | |
| JP2005526841A (ja) | 治療用１，２，３，６−テトラヒドロピリミジン−２−オン組成物及びそれを用いた方法 | |
| JP2007512270A (ja) | デオキシペガニンの経口製剤およびそれらの使用 | |
| US6627663B2 (en) | Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method | |
| US20220323343A1 (en) | Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia | |
| TWI897768B (zh) | 阿哌沙班膜產品用於治療血栓症之用途 | |
| CN107249595A (zh) | 灌肠剂 | |
| Shaikh et al. | A review on mucoadhesive drug delivery system | |
| JP2000219626A (ja) | ケロイドおよび／または肥厚性瘢痕の治療剤 | |
| CA2660565C (en) | Modafinil-based treatment for premature ejaculation | |
| RU2023130778A (ru) | Новые композиции n,n-диметилтриптамина и способы | |
| Yun et al. | Pharmaceutical devices for oral cavity-based local and systemic drug delivery |